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Learning How and Why Drugs Kill Cells
Is Chemotherapy Researchers' Prime Goal
The Division of Medicine headed
by Irwin H. Krakoff, M.D., includes
the Department of Chemotherapy
Research, in physical fact a row of
crowded laboratories and tiny offices
occupied by pharmacologists and
chemists who have one unifying
ambition: to replace the hit,or,miss
nature of cancer chemotherapy with
knowledge of how and why drugs
kill cells.
One of Krakoff' s interests in com, Irwin Krakoff
ing to Anderson from the University
of Vermont Cancer Center three years ago was to extend the
drug development program. Writing in the Cancer Bulletin of
July,August 1985, he referred to the "tremendous intellectual
and physical synergy" produced by "the interaction of
chemists, pharmacologists, toxicologists, and clinicians.''
The teams he assembled include those led by
• Edward M. Acton, Ph.D., a chemist recently recruited
from SRI International, who has made and is testing new
doxorubicin,related compounds that, according to Krakoff,
seem to be extraordinarily active;
f . . . . . , , .. ,

• Abdul R. Khokhar, Ph.D., a medicinal chemist, who is
developing a new line of platinum compounds;
• Leonard A. Zwelling, M.D., who works with DNA
topoisomerase, an enzyme that alters DNA conformation
and is a promising target for reacting with drugs that
destroy malignant but not normal cells;
• Robert A. Newman, Ph.D., a pharmacologist, who
investigates the antitumor activity of new drugs and
attempts to reduce the ill effects of some drugs now in
clinical use;
• Martin N. Raber, M.D., who works on the clinical side
of Newman's projects, testing new drugs in patients for
whom traditional therapies have failed;
• William Plunkett, Ph.D., a biochemical pharmacologist
who studies new chemotherapies for leukemia.
Among other grants, Krakoff's division has a $3 million
contract with the National Cancer Institute to test drugs in

clinical trials. "Our own program," he said, "involves the
synthesis of new chemotherapeutic agents, their study in animal
systems, their characterization as to mechanism of action and
toxicity, and finally their introduction into clinical trial.''

Chemical Synthesis of New Drugs
Dr. Edward M. Acton came from
California in February to continue
his work in drug synthesis, attracted
to Anderson because of its climate
of interaction among scientists and
physicians.
Chemical synthesis of organic
compounds, cancer drugs in parti,
cular, has been his work for 20 years.
''But you find after some time that
programs in chemical synthesis sup,
posedly targeted to new drugs don't Edward Acton
succeed very well unless you have a
chance to interact with the people who will test the drugs,
use them in the laboratory and ultimately in patients. That's
the kind of interaction I believe is superior here,'' Acton said.
Four chemists have joined him meanwhile as part of
Anderson's first organized program in chemical synthesis of
new drugs, particularly analogues of doxorubicin.
Drug evaluation involves both cell culture and animal
studies.. Properly chosen, a complementary series can yield
information about a drug's mechanism of action and tell
whether a compound is active or not, Acton explained.
''The state of the art is that tests against mouse tumors are at
best only qualitatively rather than quantitatively predictive for
human tumors-and that's another reason that understanding
mechanisms of action and how the drugs work is important.''
In talking about doxorubicin, "the most active single agent
against cancer," Acton said that more active analogues of the
drug are needed because, often, only about a third of the
patients treated can respond to the drug. Doxorubicin there,
fore is usually given in combination with other drugs.
"One of our motivations," Acton said, "is that from a better
understanding of how the drug works-of its advantages and
limitations-ought to come better analogues and an improve,
ment in chemotherapy. In theory you can triple the 30%
continued on page 2
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By next year, Khokhar and his co-investigator, Dr. Robert
A. Newman, chief of the Section of Pharmacology, expect to
have some new platinum complexes ready for clinical tests.

Learning How and Why
Drugs Kill Cells . . .
continued from page 1

Cisplatin leaves much
room for improvement.

response rate. That may not be realistic, but perhaps doubling
it is."

New Platinum Compounds
Dr. Abdul R. Khokhar came to
Houston with Krakoff to continue
working on a third generation of
platinum-based antitumor drugs,
specifically to synthesize and characterize new diaminocyclohexane platinum complexes. The prototype
platinum drug is cisplatin, used for
treating patients for testicular, lung,
liver, and ovarian cancers.
Cisplatin, Khokhar explained,
leaves much room for improvement Abdul Khokhar
because it produces toxic side effects
in kidney, nervous system, and ears, causes nausea and
vomiting, produces resistance in tumor cells, and suppresses
bone marrow activity.

Khokhar listed the goals as "a broader spectrum of antitumor
activity, no cross-resistance with cisplatin, reduced myelosuppression and neurotoxicity, and less provocation of vomiting' ' than former drug versions.

Cellular Research with a DNA Enzyme
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Two steps down the hall but occupying a more distant spot
on the research spectrum is Dr. Leonard A. Zwelling, who
said, "Our research is focused on cells, not on drugs. The drugs
are tools; the cells are the object of our work."
His object is DNA topoisomerase,
an enzyme that alters the threedimensional structure of DNA
"through concerted breaking of
DNA strand-passing and strandrejoining reactions. That's what it
does in the test tube-what it does
in the cell is not clear," Zwelling
said.
The enzyme is an important
research focus because some clinically effective antineoplastic agents
Leonard Zwelling
seem to interact with DNA topoisomerase and disrupt its function. Whether that disruption is
how the drugs work remains to be seen. The information is
vital, Zwelling said, because the same drugs that disrupt
topoisomerase can also kill malignant cells selectively-and "if
you learn how the drugs kill malignant but not normal cells,
you obviously have a handle on biochemical differences
between malignant and normal cells."
The drugs his group studies in relation to DNA topoiso-TTI
- erase- include- doxorubicin- and-.-t-he
ne-wer- compoundsamsacrine and etoposide.

Drugs are probes for malignant
phenotype.

In the course of their work with human leukemia cells and
amsacrine, Zwelling and his associates found that new leukemia cell generations are resistant to the compound. This
July-September 1986

difference between parent and daughter cells raises the hope
" that we might be able, in a sense, to test the drug sensitivity
of leukemia cells in a patient,'' he said. ''Right now, much
cancer therapy is empirical. If we had a specific biochemical
reaction that is the critical determinant of a drug's action, we
could ask the biochemical rather than the more phenomenological question, which is whether the cells live or die.
"Since the drugs we work with can in a sense distinguish
between malignant and normal cells, they become probes for
the malignant phenotype. At least part of the system can now
be studied."

''The only way to approach this is to go back to the
subcellular level and ask specifically what a drug does to a
malignant and to a normal cell-and then take advantage of
what we find out in designing better drugs, drugs that affect
malignant cells in a selective manner."

Try to reduce toxicity without
lowering efficacy.

Bring Clinical Problems to Lab

On Clinical Side

Dr. Robert Newman's pharmacology team, in addition to basic
research with bleomycin, anthracycline, and platinum derivatives,
works closely with physicians who
administer investigational drugs in
phase 1 clinical trials. This is the
phase at which "we have only a
limited idea of the drugs' antitumor
activity and the kinds of toxicity
the drugs may produce in human
beings,'' he said. ''We bring some Robert Newman
of the clinical problems shown by
these trials back to the laboratory to see if we can solve or at
least understand them. We have some clues, of course, based
on studies in mice and dogs, but human beings are different
animals.''
Newman's group recently studied the molecular pharmacology, antitumor activity, and neurotoxicity of caracemide and
nafidimide, investigational drugs from the National Cancer
Institute. He, too, expressed the hope of "bringing to the
clinic in the next couple of years some of the compounds
developed by our system, drugs that will provide the best
chemotherapy for the patients and yet not compromise their
quality of life. We're trying to do that by looking at
toxicity associated with these drugs and reducing it without
reducing the drugs' efficacy," he said.
-Newman studies doxorubicin and bleomycin because,
although these drugs work well against cancer, the first
sometimes causes congestive heart failure and the second may
contribut~ to pulmonary fibrosis. In both cases, the goal of his
research is to come up with less toxic drug versions-Newman's
group is testing an improved bleomycin analogue-and, in the
course of this, to find out how the drugs work.
"We all have some very naive assumptions of how drugs kill
cells," Newman said. "When it comes down to answering specifically how a drug kills cells, one can go to a textbook for some
very trite answers. Drugs kill cells in many different ways, and
defining which one is more important and which one we should
concentrate on in terms of developing a better drug is difficult.

"Newman and I," said Dr. Martin N. Raber, chief of
the Section of New Drug Studies, "use the laboratory's
pharmacologic studies to design a clinical trial. As the trial
goes along, if we see results and begin to understand the drug's
pharmacologic activity in the patient, we can modify the trial
according to laboratory information on drug metabolism and
toxicity.
''One has to understand clearly
who the patient is and what we are
doing," Raber stressed. "The patient
is one who has failed to respond to
conventional treatments, and the
drug has been used only in animals
and laboratory trials.
''We ask the patient to take this
drug at ever-increasing dosages until
a toxic reaction occurs." Patients
who agree to do this, he said,
understand that the treatment is Martin Raber
"statistically unlikely to work." Yet
they consent to participate in the study because of the small
chance that the treatment will be effective-and, Raber added,
"because someone else is likely to benefit from it."
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Patients easy to work with
and staff committed to them.
These highly motivated patients are willing to undergo
pharmacologic tests that go beyond treatment effectiveness to
more basic information about drug action. Although some
patients in phase 1 studies may experience serious side effects
from new drugs, Raber said, "in the final analysis a drug's
activity and toxicity can only be tested in patients. The dog
and the mouse can't tell you that they feel confused or that the
drug causes a burning sensation in the mouth. So, the final
experiment is always the human experiment. This work is not
continued on page 6
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Grant Taylor Organized First Collaborative
Drug Research Group in This Part of the Country
H. Grant Taylor, M.D., has a lecture series named for him,
and his portrait hangs at the entrance to the sixth-floor
pediatric unit of Anderson Hospital, the unit he directed from
the first day, March 19, 1954, the hospital opened in the Texas
Medical Center.
Taylor is also the founder of this
area's first collaborative drug study
program, the Southwest Cancer
Chemotherapy Study Group, a
bridge between scientists who until
then tended to work competitively
and in isolation.
Luckily, in this year of historical
reminders, Taylor is present in pictures and in person because he is 83,
not 150 years old. One can't celebrate a sesquicentennial of cancer H. Grant Taylor
research or of treatment of children
for cancer because the history of these endeavors does not go
back that far.
Taylor is one of this cancer center's early activists and
theoreticians. His work spans nearly the entire history of the
UT M. D. Anderson Hospital. Now an emeritus professor of
pediatrics at Anderson and still working in the UT Health
Science Center Division of Continuing Education-he headed
the di~ ion's forerunner, the UT Postgraduate School of
Medicine-his so-called retirement consists of writing and
teaching and seeing patients one day a week in a City of
Houston pediatric clinic. His definition of "part time" leans
toward everyone else's "full time."

education, after growing up in a pioneer farming family on the
Canadian prairie, nurtured his talent for building links. He
managed to do this among solo researchers and doctors in
private practice, and between Japanese research fellows and
Houston citizens with World W ar II memories and antiJapanese prejudices.
In the early 1950s, when Taylor was recruited from the
National Academy of Sciences to become chief of pediatrics at
Anderson, he says " I was warned not to come here because I
was told the place was a medical intellectual desert. Yet here
the M. D. Anderson Foundation had the foresight to help
finance the Texas Medical Center and make it possible, by
matching state funds with private money, for The University
of Texas to establish a cancer hospital. So in this state there
were lots of enlightened forces. "

Lesson of war: work on teams
and forget sell
Taylor believes it was his war experience as an Army
physician and his later service with the Atomic Bomb
Casualty Commission in Hiroshima that brought him home with
the idea that cancer research should be done collaboratively.
"After the war," he says, "everybody was working alone, with
no cooperation. And yet I think one of the biggest lessons of
that ·time was that people had to work on teams and forget
self."

Preaching and Recruiting

He is one of cancer center's
activists and theoreticians.

Taylor is loved for his comforting and confident professional
care, his willingness to try new methods of cancer treatment,
and his efforts to broaden the world's knowledge of cancer by
extending learning opportunities to physicians and researchers
from other countries. Now he has the joy of seeing one son as
head of the oncology service of Walter Reed Army Medical
Center and the other as administrator of the Air Force
hospital at Wichita Falls.

Talent for Connecting People
Taylor earned degrees in engineering and education before
he graduated from medical school at age 37. Perhaps this broad

4

In 1958, he organized the Southwest Cancer Chemotherapy
Study Group with a grant from the U.S. Public Health Service
(PHS), the first collaborative research group in this part of the
country. Taylor was making rounds preachin g and recruiting' 'talking about getting together because we had to have a
vo ume o patients to earn more a out treatment, an we a
to have collaborative laboratory research to back it up," he
says.
Early members of the research group were teams at UT sister
institutions in Galveston and Dallas, at Baylor College of
Medicine, the Veterans Administration Hospital in Houston,
the University of Arkansas Medical School, and Tulane
University. Ten years later, the Southwest group had spread
north to Chicago, Detroit, and Minneapolis, and east to
Atlanta and Memphis, until it involved 20 institutions and
some 80 researchers.
As Taylor recalls with some glee, the idealistic research
July-September 1986

Hard Lesson

cooperative worked on a hard-nosed principle: "I got the grant
for the cooperative chemotherapy study group from PHS, and
the grant stated that researchers who became members could
then apply for a grant to cooperate with us. We were the
umbrella organization for 'A Cooperative Study in the Com,
parative Evaluation of Hydrocortisone Used Alone and in
Combination with a Mercaptopurine in the Treatment of
Acute Leukemia.' ''
The drugs were two of many to follow that would produce
complete remissions in some leukemic children.

Among the new drugs barely tested at that time was
vincristine. As Taylor tells it, "I had gone to a meeting in
Indianapolis where I was given some vincristine, and I gave the
first dose to a child who had a tumor. It was a brand-new drug,
tested in animals, but the dosage I gave the child was too high,
and he went into convulsions that lasted seven days. The day
after the convulsions stopped, the child's X ray showed that
the tumor had disappeared. That was our first time that
vincristine was a success, despite that horrible blunder."

Texas Nonwelcome

Light from Sixth Floor

Wataru W. Sutow, M.D., who died in 1982, is seldom
absent from Taylor's conversation. He is the Japanese-American
physician-interned with his family during the war even
though he was born in this country-with whom Taylor
worked in Japan and later recruited to head Anderson's
research with children. Well remembered, too, are the
Japanese research fellows whom Taylor and Sutow trained and
who now head major Japanese medical institutions.

Taylor describes the accomplishments of his career with a
fresh memory and sense of drama. The heroes of his stories are
associates and students and, above all, the parents of his young
patients. When his two sons were children, he used to tell them
that the glow at night from the pediatric unit sixth-floor
windows was made by the mothers' and fathers' care for their
children.
"I think today of those mothers and fathers, who gave us
permission to try new drugs we knew so little about,'' Taylor
says.
''That was perhaps the most magnanimous gesture I have ever
witnessed in my life, for a mother to say: 'Doctor, I understand
you can't help our little boy, but if you can learn something
that might help somebody else, go ahead and do it.' It was
expensive for families to stay here, they were upset, and yet
they did that.
"If they hadn't done it then, the mothers and fathers today
would be right in their place. We were partners."

Led by Satow,
research with children moved
forward fast.
When they were first invited to Houston in the 1950s, these
young Japanese physicians were welcome only where they
worked. They found it difficult to find a place to live until a
church congregation got involved in helping them become
more accepted by the community. Sutow and his family also
would have been homeless at first, Taylor says, if a realtor had
not moved out of his house so that the Sutows could live there.
Under Sutow's leadership, research with children moved
forward faster than research with adults because, as Taylor
says, "Pediatrics was really the leading edge. Research with
children is easier because the disease is more clearcut in
c i ren an not comp 1cate y pro ems o agmg. urt er,
more, we had some drugs for leukemia-methotrexate among
them-and a response that could be measured.''
Taylor is particularly proud of the 34 Japanese physicians
trained at Anderson during those years, despite the problems.
"In a way," he says, "one of our hospital's major international
contributions was the training of people and their going home.
The Japanese did much with what they learned here. Their
society was moving forward fast, and so they went right ahead
with what they learned."

Vol. 31, No. 3

Taylor describes his career with
a fresh memory and sense of
drama. His heroes are associates
and students and, above all, the
parents of his young patients.
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Learning How and Why Drugs Kill Cells . . .
continued from page 3
for the faint-hearted, neither patient nor doctor."
Raber talked about the strong support among nurses, social
workers, physicians, chaplains, and psychiatrists. Staff members
carry a tough emotional load because the majority of patients
taking new drugs are very ill and may soon die, despite every
therapeutic effort. Nevertheless, the patients are easy to work
with, he said, because they take such an active part in their
own care.
"The staff at Anderson is very committed to the patients.
And I find that patients, particularly young ones, like it here
because here they're not thought of as freaks. In the general
hospital, the 26-year-old woman with lung cancer is an
anomaly. She's lost her hair, she's very thin, everyone looks at
her strangely and thinks how tragic she is. But when she walks
into the Anderson hospital, people treat her as just another
patient. She fits in," he said.
Raber is proud of his section's "compulsive" record-keeping
and complete computerization, which improve the reliability
of drug trial data, and he is well acquainted with the fact that
researchers' and drug companies' goals may be different: the
company wants to prove a drug is worthwhile and should be
approved by the Food and Drug Administration, whereas the
researcher may have a more objective view. Both want to find
"the most efficacious way to use the drug, the best dosage, best
schedule, and most responsive tumor to use it on. The design
of trials," he said, "is a complicated problem."
And, he added almost seriously, testing drug analogues is
like "digging oil wells in Texas today. You know there's oil
down there-you just want to come up with it in an easier way."

Optimistic and Impatient
One characteristic of the Department of Chemotherapy
Research is a mixture of optimism and impatience. Krakoff
pointed to "enormous improvements" in the ability to cure
neoplasms like acute lymphoblastic leukemia, testicular cancer,
and Hodgkin's disease, "marked advances" in treating head
and neck cancer, and "some progress" in treating breast and
ovarian cancer. But the successes highlight the failures , he
said, because ''we still do very little for many of the
common cancers-for example, those of colon, lung, pancreas,
and others. Perhaps those tumors must be approached by
different principles, but it is more likely that the principles
shown to be successful for treating some tumors would be
successful in others if we had better or more specific drugs.''

Successes
highlight failures.
Bleomycin, doxorubicin, and cisplatin ''have been around
for a decade or more, which means that new ones are needed,"
he said.

(Physicians who desire additional information may write Irwin H.
Krakoff, M.D., Division of Medicine, Box l5, The University of
Texas M. D. Anderson Hospital and Tumor Institute at Houston,
6723 Bertner Avenue, Houston, Texas, 77030.)

Tes ting Leukemia Treatments
Dr. William Plunkett, who conducts studies of new drugs and new
treatment regimens in leukemic
patients who can no longer benefit
from other therapies, sums up his
work as "trying to target effective
treatment at susceptible disease."
Plunkett's recent investigations
have focused on effective dosage,
therapeutic efficacy, and pharmacologic correlates of arabinosylcytosine
(ara..C) in patients with refractory William Plunkett
acute leukemia. These patients
differ greatly in their ability to metabolize ara..C, he explained.
His research group's finding of a relationship between the
ability to achieve remission and the inhibition of DNA
synthesis by ara..CTP, an ara..C metabolite, has been a clue to
knowing the metabolic characteristics of the leukemia likely
to improve with this drug.
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Thirty-ninth Annual Symposium
on Fundamental Cancer Research

Critical Molecular Determinants
in Carcinogenesis

September 16-19, 1986
Stouffer's Greenway Plaza Hotel
Houston
For registration information, contact Shirley Roy, Office of
Conference Services, HMB Box 131, The University of Texas
M. D. Anderson Hospital and Tumor Institute, 6723 Bettner
Avenue, Houston, Texas 77030, (713) 792-2222.
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Science Park Hosts First
Texas Carcinogenesis Meeting
The Texas C arcinogenesis Meeting at UT System Cancer
Center Science Park-Research Division in April was the first
of what are to be twice-yearly meetings for Texas scientists to
discuss research in carcinogenesis, the biology of cancer, genetic
toxicology, and mutagenesis. Financial support for the all-day
conference, attended by 103 professionals and students from 14
institutions, came from the Texas Division of the American
Cancer Society.
In the keynote address, J. Carl Barrett, Ph.D., National
Institute of Environmental Health Science at Research
Triangle Park, N.C., reported his work on the molecular
action of tumor promotion. Barrett and his colleagues are the
only researchers currently doing in vitro studies of the genes
that suppress tumor growth.
Milton Marshall, Ph.D., Southwest Foundation for Biomedical Research at San Antonio, described his research with
baboons on smoking and cancer. Marshall has been able to
train primates to duplicate human cigarette smoking, and he is
beginning to quantitate his data on the presence of mutagens
in the animals' blood, urine, and other specimens.
Rebecca Morris, Ph.D., Science Park-Research Division,
reported on the retention by epidermal cells of benzo(a)pyrene,
a ubiquitous carcinogen formed by combustion of hydrocarbons.

Morris has used radiolabeling techniques to determine that
benzo(a)pyrene may remain in the skin for up to one month
after exposure.
Jonathan Ward, Ph.D., UT Medical Branch at Galveston,
discussed his study of risks of contact with pollutants along the
Gulf Coast. Ward exposes mice to the most common pollutants
and then assesses their effects on the animals' organ systems.
Organizers of the Texas Carcinogenesis Meeting want to
hold these sessions at different institutions in the state and to
encourage a lively exchange of information in an informal
setting. They invite postdoctoral fellows and graduate students
to attend and submit abstracts for the poster sessions.
The meetings are ·open to all interested persons, including
specialists in other fields who wish to extend their knowledge
of the biology of cancer and related phenomena.
The next Texas Carcinogenesis Meeting, Nov. 11 at the Hotel
Inter-Continental in Houston, will coincide with the 30th
Annual Clinical Conference on Cancer, ''Current Approaches
to the Diagnosis and Treatment of Gastrointestinal Cancer.''

(For more information contact the Office of Conference
Services,HMB Box 131, UT M. D. Anderson Hospital and
Tumor Institute, 6723 Bertner Avenue, Houston, Texas 77030;
713-792-2222.)

Cancer Prevention Begins at Home:
·With MD A Screening and Detection Clinic
Helping M. D. Anderson staff
members apply principles of prevention and early detection of
cancer to their own lives is the goal
of the employee screening program
directed by Linda N. White, R.N.,
with medical direction by J. Taylor
arton, . ., pro essor ,o gynecology.
According to its Ten Year Report,
the Cancer Screening and Detection
Program aims ''to increase the Linda White
accessibility, availability, and
quality of cancer prevention and detection services by
training nurses to assume a direct and collaborative role
with physicians in all health care settings, and to reduce the
impact and costs of cancer by lowering the risk of developing
it.''

Vol. 31, No. 3

A worthwhile goal-and it is working, according to White
and clinic coordinator Judy Faulkenberry, R.N. The fullfledged cancer screening program was established in June 1981
after a pilot program tried in 1980 turned out to be overwhelmingly popular. Today, cancer screening for employees is
a full-time operation, run by nurses and supervised by an
advisory board of physicians with specialties in gynecologic,
gastrointestina , an reast cancers, an in mammograp y an
diagnostic radiology.
The physicians helped establish the examination protocols,
which include a thorough examination of skin, head and neck,
breasts, lungs, abdomen, female genitalia, rectum, male
genitalia, and lymph nodes. An assessment of cancer risk is
based on a detailed medical and family history questionnaire
staff members fill out. They are taught self-examination
techniques and given cancer education booklets. When
appropriate, employees are referred for additional tests.
continued on page 8
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Cancer Prevention Begins
at Home ...
continued

from page
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As of last March, 3,199 Anderson staff members who were
asymptomatic for cancer had been examined; 874 were found
to have noncancerous abnormalities that required medical
attention, and 49 had premalignant conditions. Twelve
cancers were detected.
Asked for their reactions to the clinic's services, the
staff's helpfulness, and the thoroughness of the examination in
written evaluations six months after their clinic visits,
Anderson employees gave the program a close to excellent
rating, 6.5 on a scale of 1 to 7. One of the most
encouraging results is that 86.4% of the women and 90.3% of
the men shared the information they had received with friends
and family members. Most of the screened employees, both
men and women, did self-examinations more often.
Clinic, White says, con
t in ues to train nurse
specialists from other Texas
institutions and to help
companies-Johnson &
Johnson, for example-to
start cancer screening Cancer detection specialist
programs for their own Alice Judkins with client.
employees.
(Physicians who desire additional infarmation may write Linda
N. White, R.N., Cancer Prevention and Detection Program,
Box l33, The University of Texas M. D. Anderson Hospital and
Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030.)
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The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston
Thirtieth Annual Clinical Conference on Cancer

Current Approaches to the Diagnosis
and Treatment of Gastrointestinal Cancer

November 11-15, 1986
Hotel Inter-Continental • Houston
Chaired by Bernard Levin, M.D.

Chief, Section of Gastrointestinal Oncology
and Digestive Diseases
and Robert Herring Professor in Clinical Research

In eight sessions and 45 lectures and panel
discussions, the conference will provide informa
tion on the best in diagnosis and treatment for this
type of disease. It will be a forum for sharing new
ideas and learning about advances.
Registration fees are $285 (advance)
and $325 (after Oct. 20).
For registration information, contact Shirley Roy, Office of
Conference Services, HMB Box 131, The University of Texas
M. D. Anderson Hospital and Tumor Institute, 6723 Bettner
Avenue, Houston, Texas 77030, (713) 792-2222.

